| Date | Title | | | May.20.13 | Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company| - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -
- Expands Portfolio and Pipeline in Core Areas of Women's Health and Urology -
- Adds Gastroenterology and Dermatology Franchises and Infrastructure -
- Stronger Commercial Presence to Support Expanded Brand Pipeline -
- Immediately Accretive With Opportunities for Substantial Operational Synergies and Tax Savings -
- Combination Expected to Generate Strong EBITDA and Cash from Operations -
- All Stock Transaction Fu... |
|  | | May.14.13 | Announcement Under Irish Takeover Rules Relevant Securities in Issue| PARSIPPANY, N.J., May 14, 2013 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Rules, Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, (the "Company") confirms that, as at the latest practicable date prior to the making of this announcement, the Company's issued share capital consisted of 133,305,212 ordinary shares, excluding treasury shares, par value US$0.033 per share (the "Ordinary Shares"). The International Securities Identification Number for these ... |
| | | May.13.13 | Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA| PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy.
The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. The acceptance for f... |
| | | May.13.13 | Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference| PARSIPPANY, N.J., May 13, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has cancelled its appearance at the upcoming Bank of America Merrill Lynch Healthcare Conference. Actavis had been scheduled to present on Tuesday, May 14, 2013 at 8:40 AM Pacific Time at the Encore at the Wynn in Las Vegas, Nevada.
About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on ... |
| |
|
Country websites
